Literature DB >> 3368074

Excitatory amino acids are elevated in human epileptic cerebral cortex.

A Sherwin1, Y Robitaille, F Quesney, A Olivier, J Villemure, R Leblanc, W Feindel, E Andermann, J Gotman, F Andermann.   

Abstract

We used intraoperative electrocorticography to identify and compare specimens from two groups of patients undergoing temporal lobectomy: (1) spiking cortex (12 patients)--epileptic activity recorded over much of the temporal convexity; and (2) nonspiking cortex (9 patients)--temporal convexity free of interictal spiking, epileptic activity confined to the hippocampus and/or amygdala. Comparative amino acid levels were (mumol/g protein, mean +/- SEM): glutamate--spiking 109.8 +/- 1.8, nonspiking 87.4 +/- 2.0 (p less than 0.001); aspartate--spiking 15.2 +/- 0.9, nonspiking 12.2 +/- 0.5 (p less than 0.05); GABA--spiking 15.0 +/- 1.0, nonspiking 13.9 +/- 1.4 (NS); taurine--spiking 14.5 +/- 0.8, nonspiking 12.2 +/- 0.8 (NS); and glycine--spiking 11.5 +/- 0.8, nonspiking 7.4 +/- 0.6 (p less than 0.01). Cortical epileptic activity appears to be associated with elevated concentrations of glutamate, aspartate, and glycine, but not GABA and taurine, perhaps indicating a relative imbalance between putative excitatory and inhibitory amino acid neurotransmitters.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3368074     DOI: 10.1212/wnl.38.6.920

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging.

Authors:  L P Mark; R W Prost; J L Ulmer; M M Smith; D L Daniels; J M Strottmann; W D Brown; L Hacein-Bey
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

2.  Decreased glutamate transport enhances excitability in a rat model of cortical dysplasia.

Authors:  Susan L Campbell; John J Hablitz
Journal:  Neurobiol Dis       Date:  2008-07-15       Impact factor: 5.996

3.  Comparative analysis of seizures induced by intracerebroventricular administration of NMDA, kainate and quisqualate in mice.

Authors:  C Mathis; A Ungerer
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

Review 4.  Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.

Authors:  O A Petroff; D L Rothman
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

5.  Increased expression of the neuronal glutamate transporter (EAAT3/EAAC1) in hippocampal and neocortical epilepsy.

Authors:  Peter B Crino; Hong Jin; Melissa D Shumate; Michael B Robinson; Douglas A Coulter; Amy R Brooks-Kayal
Journal:  Epilepsia       Date:  2002-03       Impact factor: 5.864

6.  Effect of a noncompetitive antagonist (MK-801) of NMDA receptors on convulsions and brain amino acid level in E1 mice.

Authors:  K Sato; K Morimoto; M Hiramatsu; A Mori; S Otsuki
Journal:  Neurochem Res       Date:  1989-08       Impact factor: 3.996

7.  Quantitative MR spectroscopy reveals metabolic changes in the dorsolateral prefrontal cortex of patients with temporal lobe epilepsy.

Authors:  Qiaoyue Tan; Huaiqiang Sun; Weina Wang; Xintong Wu; Nanya Hao; Xiaorui Su; Xibiao Yang; Simin Zhang; Jingkai Su; Qiang Yue; Qiyong Gong
Journal:  Eur Radiol       Date:  2018-05-04       Impact factor: 5.315

8.  Comparison and effects of acute lamotrigine treatment on extracellular excitatory amino acids in the hippocampus of PTZ-kindled epileptic and PTZ-induced status epilepticus rats.

Authors:  Yan Deng; Minghuan Wang; Wei Wang; Chao Ma; Nongyue He
Journal:  Neurochem Res       Date:  2012-12-11       Impact factor: 3.996

9.  Increased plasma glutamic acid in a genetic model of epilepsy.

Authors:  N A Janjua; H Kabuto; A Mori
Journal:  Neurochem Res       Date:  1992-03       Impact factor: 3.996

10.  Involvement of synaptosomal neurotransmitter amino acids in audiogenic seizure-susceptibility and -severity of Rb mice.

Authors:  S Simler; L Ciesielski; J Clement; A Rastegar; P Mandel
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.